FDA approves Bristol Myers Squibb's schizophrenia drug
WEB1 day ago — The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
First new type of treatment for schizophrenia in decades - NPR
WEB2 hours ago — For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by Bristol Myers Squibb will be called ...
Bristol Myers wins US FDA approval for new type of schizophrenia …
WEB1 day ago — Sept 26 (Reuters) - The U.S. Food and Drug Administration approved Bristol Myers Squibb's (BMY.N) schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers …
WEB11 hours ago — On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB12 hours ago — PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
U.S. Food and Drug Administration Approves Bristol Myers …
WEB22 hours ago — COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol ...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia …
WEB1 day ago — Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
Bristol Myers Squibb Stock Rises After Schizophrenia
WEB9 hours ago — Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration. The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia …
WEB4 hours ago — Shares in Bristol-Myers Squibb (BMY) rose Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 1.8% higher in ...
FDA approves Bristol Myers Squibb's new schizophrenia drug
WEB8 hours ago — Cobenfy is the first novel treatment for schizophrenia in decades. Cobenfy was approved the U.S. Food and Drug Administration (FDA) on Sept. 26. Image: Bristol Myers Squibb. The U.S. Food and Drug ...